Showing 1381 to 1395 of 2527 results
Conflict of interest policy updated
The new Conflict of interest policy for partners is now available
Performance review - more information
More details about aspects of the performance review process.
Update on our registration fees
Your concerns, arguments, and views about the impact of HCPC’s proposed fee rise have prompted us to re-think our approach.
Our equality, diversity and inclusion strategy 2021-26
Our EDI strategy sets out how the HCPC intends to achieve our overarching vision of an actively anti-discriminatory organisation, and is supported by an EDI action plan
Corporate strategy
Our corporate strategy for 2026-2031, including our vision, mission, aims and priorities.
We've launched our new data hub
Our new data hub, provides a valuable insight into the 15 health and care professions that we regulate.
Standards of education and training review: Public workshop
An online workshop for members of the public on our review of the standards of education and training (SETs). We'll give an overview of the review process and go through some of the changes we are proposing.
Standards of education and training review: Public workshop
An online workshop for members of the public on our review of the standards of education and training (SETs). We'll give an overview of the review process and go through some of the changes we are proposing.
Confidentiality and accountability
You need to make informed and reasonable decisions about your own practice to make sure that you always respect and protect the confidentiality of service users
Continuing professional development workshops in Birmingham
Three workshops that explain the HCPC's standards for CPD, along with examples of activities and evidence
Continuing professional development workshops in Glasgow
Two workshops that explain the HCPC's standards for CPD, along with examples of activities and evidence
Meet the HCPC, Wrexham
Meet the HCPC (Wrexham) is a chance to hear about our recent work, ask us questions and share ideas
Joint statement on meeting regulatory standards during periods of global or national shortage of medicines
We are concerned to hear that people with Type 2 diabetes are experiencing problems accessing GLP-1 receptor agonists (GLP-1 RAs).